# A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

> **NCT03316794** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 2 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SC-005

## Key facts

- **NCT ID:** NCT03316794
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-04
- **Primary completion:** 2018-10-05
- **Final completion:** 2018-10-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2018-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316794, "A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03316794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*